Mineralocorticoid antagonists in chronic kidney disease
- PMID: 27753685
- DOI: 10.1097/MNH.0000000000000290
Mineralocorticoid antagonists in chronic kidney disease
Abstract
Purpose of review: Current evidence showcases the pathologic effects of excess aldosterone in promoting glomerular and tubulointerstitial inflammation and fibrosis through various pathways. The place for mineralocorticoid receptor antagonists (MRAs) in chronic kidney disease (CKD) progression is unclear.
Recent findings: MRAs further reduce albuminuria and blood pressure in CKD patients when used in conjunction with angiotensin-converting enzyme inhibitor or angiotensin receptor blockers. The usage of MRAs as disease-modifying therapy in CKD patients has been hampered by concern over worsening kidney function and hyperkalemia. Recent data from small studies highlight a way that these agents may be used with no fear of hyperkalemia. Additionally, they have been shown to further lower blood pressure and albuminuria when hyperkalemia is no longer a safety issue. Additionally, novel MRAs are in phase 3 clinical trials and these are discussed.
Summary: MRAs have a clear role in further reducing very high albuminuria when used with other renin-angiotensin system blockers; however, hyperkalemia is a limiting factor for the use of MRAs. Use of the new potassium binder patiromer has facilitated the use of MRAs in CKD, and novel nonsteroidal MRAs are currently being tested in advanced CKD outcome trials.
Similar articles
-
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.Kidney Int. 2016 Sep;90(3):696-704. doi: 10.1016/j.kint.2016.04.019. Epub 2016 Jun 24. Kidney Int. 2016. PMID: 27350174 Clinical Trial.
-
Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.Cardiorenal Med. 2020;10(1):32-41. doi: 10.1159/000503223. Epub 2019 Oct 30. Cardiorenal Med. 2020. PMID: 31665724
-
Nonsteroidal antagonists of the mineralocorticoid receptor.Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. doi: 10.1097/MNH.0000000000000147. Curr Opin Nephrol Hypertens. 2015. PMID: 26083526 Review.
-
Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.Am J Nephrol. 2024;55(1):1-17. doi: 10.1159/000534366. Epub 2023 Oct 4. Am J Nephrol. 2024. PMID: 37793348
-
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.Kidney Int. 2019 Aug;96(2):302-319. doi: 10.1016/j.kint.2019.02.030. Epub 2019 Mar 13. Kidney Int. 2019. PMID: 31133455 Review.
Cited by
-
How to Choose the Right Treatment for Membranous Nephropathy.Medicina (Kaunas). 2023 Nov 14;59(11):1997. doi: 10.3390/medicina59111997. Medicina (Kaunas). 2023. PMID: 38004046 Free PMC article. Review.
-
Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).Clin Kidney J. 2023 Mar 22;16(9):1384-1402. doi: 10.1093/ckj/sfad055. eCollection 2023 Sep. Clin Kidney J. 2023. PMID: 37664575 Free PMC article. Review.
-
[Current aspects of heart-kidney interactions : Summary of important clinical studies from 2020].Herz. 2022 Apr;47(2):150-157. doi: 10.1007/s00059-021-05043-0. Epub 2021 Jun 9. Herz. 2022. PMID: 34106300 Free PMC article. Review. German.
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
-
The role of aldosterone in the pathogenesis of diabetic retinopathy.Front Endocrinol (Lausanne). 2023 Apr 11;14:1163787. doi: 10.3389/fendo.2023.1163787. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37113483 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials